Specify a stock or a cryptocurrency in the search bar to get a summary
Fennec Pharmaceuticals Inc
FRXFennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina. Address: 68 TW Alexander Drive, Research Triangle Park, NC, United States, 27709
Analytics
WallStreet Target Price
131.6 CADP/E ratio
59.8Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures FRX
Dividend Analytics FRX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History FRX
Stock Valuation FRX
Financials FRX
Results | 2019 | Dynamics |